What is the drug approval number?

The drug registration and approval number is 10960198.

Where is the nearest shipping port?

Nearest ports include Tianjin Xingang, Qingdao, and Shanghai.

Fluconazole I. V. Infusion GMP Manufacturer

Name: Fluconazole I. V. Infusion GMP Manufacturer
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 853936955

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.30-0.40

20,000 Pieces

Sample price:US$0.10/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Injection

Model NO.

100ml: 200mg

Suitable for

Elderly, Adult

State

Liquid

Shape

Injection

Type

Injection

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

10960198

Production Line

GMP Approved

Transport Package

Carton

Specification

100ml

Trademark

SHIMEN

Origin

Hebei

HS Code

3004909099

Production Capacity

1000000

Key features

GMP Approved Production: Manufactured on GMP approved production lines ensuring international quality standards.

Chemical Synthesis Technology: Utilizes advanced chemical synthesis pharmaceutical technology for high purity.

Anti-Fungal Efficacy: New triazole agent effectively restraining fungal sterol combination for infections.

Clear Liquid Formulation: Product is colorless and pellucid liquid suitable for intravenous injection.

Global Export Reach: Products exported to over 80 countries across Asia, Americas, Europe, Africa, and Oceania.

70-Year Brand History: Shijiazhuang No. 4 Pharmaceutical Co., Ltd. has a 70-year history in the industry.

Full Automation Control: Production and logistics processes feature full automation and information control.

Top 100 Enterprise Status: Recognized as one of China's top 100 pharmaceutical industry enterprises.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤18hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.